GlassScriptPhysician profile
Amit Aravapalli
NPI 1912169905
$7,655.49
in general payments reported to CMS, 2019-2025
30 companies · $1,512 in 2025
The $1,512 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,847 · 2020: $469 · 2021: $823 · 2022: $1,106 · 2023: $1,061 · 2024: $837 · 2025: $1,512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,366 · Debt Forgiveness: $43.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,365.66 |
| Debt Forgiveness | $43.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,124.25 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $926.64 | 2019-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $657.56 | 2019-2025 | Xifaxan |
| Gilead Sciences, INC. | $588.42 | 2019-2025 | |
| Genzyme Corporation | $552.24 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $491.98 | 2019-2025 | Entyvio, Eohilia |
| Intercept Pharmaceuticals, INC. | $318.61 | 2019-2024 | Ocaliva |
| Alnylam Pharmaceuticals INC. | $274.74 | 2020-2024 | Givlaari |
| Qol Medical, LLC | $182.70 | 2019-2023 | Sucraid |
| Ferring Pharmaceuticals INC. | $169.01 | 2019-2023 | Rebyota |
| Celltrion USA INC. | $165.15 | 2025 | Zymfentra, Vegzelma |
| Regeneron Healthcare Solutions, INC. | $161.22 | 2022-2025 | Dupixent |
| Cook Medical LLC | $139.33 | 2025 | Hemospray |
| Echosens North America, INC. | $114.76 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $85.27 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $82.63 | 2019-2023 | Linzess |
| Pfizer INC. | $77.03 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $73.41 | 2022 | |
| Celgene Corporation | $67.07 | 2022-2023 | Zeposia |
| Boston Scientific Corporation | $60.07 | 2024-2025 | General - Enteral Feeding, Watchman Flx |
| Braintree Laboratories, INC. | $59.41 | 2019-2021 | |
| Lilly USA, LLC | $51.37 | 2024 | Omvoh |
| Baxter Healthcare | $43.93 | 2023 | |
| Merck Sharp & Dohme LLC | $40.87 | 2019-2022 | |
| Redhill Biopharma INC. | $33.45 | 2022-2023 | Talicia, Aemcolo, Movantik |
| Shionogi INC | $29.12 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $24.55 | 2024 | Voquezna |
| Medtronic, INC. | $23.50 | 2023 | Gi Genius |
| Ucb, INC. | $21.41 | 2019 | |
| Masimo Corporation | $15.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Aravapalli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.